ABIOMED (ABMD) : Granahan Investment Management Incma reduced its stake in ABIOMED by 0.19% during the most recent quarter end. The investment management company now holds a total of 321,783 shares of ABIOMED which is valued at $39,801,339 after selling 600 shares in ABIOMED , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.ABIOMED makes up approximately 1.33% of Granahan Investment Management Incma’s portfolio.
Other Hedge Funds, Including , Nuveen Asset Management reduced its stake in ABMD by selling 24,466 shares or 17.99% in the most recent quarter. The Hedge Fund company now holds 111,554 shares of ABMD which is valued at $13,798,114. ABIOMED makes up approx 0.08% of Nuveen Asset Management’s portfolio.Miles Capital boosted its stake in ABMD in the latest quarter, The investment management firm added 156 additional shares and now holds a total of 2,823 shares of ABIOMED which is valued at $349,177. ABIOMED makes up approx 0.23% of Miles Capital’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in ABMD in the latest quarter, The investment management firm added 23,236 additional shares and now holds a total of 1,160,974 shares of ABIOMED which is valued at $143,600,874. ABIOMED makes up approx 0.02% of Blackrock Institutional Trust Company N.a.’s portfolio.Acadian Asset Management boosted its stake in ABMD in the latest quarter, The investment management firm added 106 additional shares and now holds a total of 119 shares of ABIOMED which is valued at $14,071.
ABIOMED opened for trading at $119.03 and hit $121.44 on the upside on Monday, eventually ending the session at $120.71, with a gain of 1.64% or 1.95 points. The heightened volatility saw the trading volume jump to 3,03,057 shares. Company has a market cap of $5,195 M.
On the company’s financial health, ABIOMED reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.24. The company had revenue of $103.00 million for the quarter, compared to analysts expectations of $97.48 million. The company’s revenue was up 40.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.